China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.
FSD Pharma has signed a binding letter of intent (LOI) to acquire Therapix Biosciences, a NASDAQ traded pharmaceutical company focused on the development of Cannabinoid-based treatments.
TP Therapeutics, a San Diego-based clinical-stage precision oncology company, has raised $80m in a new funding round led by Foresite Capital and venBio Partners.
AbbVie and Morphic Therapeutic have entered into a research and development collaboration, designed to advance multiple Morphic's oral integrin therapeutics for fibrosis-related indications.
Swiss drugmaker Novartis has agreed to acquire US-based biopharmaceutical firm, Endocyte, in a deal valued at around $2.1bn.
Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
US-based Revolution Medicines has acquired Warp Drive Bio for an undisclosed sum as part of its efforts to expand drug discovery portfolio.
HiFiBiO Therapeutics has acquired H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.
Alliqua BioMedical has entered into a merger agreement with Adynxx to create a clinical-stage pharmaceutical firm, which will focus on development of therapies for pain and inflammation.
Carrick Therapeutics has acquired global licensing rights to develop and commercialize BTG’s ovarian cancer drug BTG945, which has been renamed as CT900.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.